427 related articles for article (PubMed ID: 24229637)
1. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Del Rosso JQ
J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S44-56. PubMed ID: 24229637
[TBL] [Abstract][Full Text] [Related]
2. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
4. Medical Management of Facial Redness in Rosacea.
Cline A; McGregor SP; Feldman SR
Dermatol Clin; 2018 Apr; 36(2):151-159. PubMed ID: 29499798
[TBL] [Abstract][Full Text] [Related]
5. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Patel NU; Shukla S; Zaki J; Feldman SR
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
[TBL] [Abstract][Full Text] [Related]
6. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
8. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
Hoover RM; Erramouspe J
Ann Pharmacother; 2018 Mar; 52(3):263-267. PubMed ID: 29094614
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
11. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Del Rosso JQ; Thiboutot D; Gallo R; Webster G; Tanghetti E; Eichenfield LF; Stein-Gold L; Berson D; Zaenglein A;
Cutis; 2014 Mar; 93(3):134-8. PubMed ID: 24738094
[TBL] [Abstract][Full Text] [Related]
12. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
Hsia E; Tian M; Gil D
Exp Dermatol; 2018 Jul; 27(7):763-768. PubMed ID: 29637626
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline.
Shanler SD; Ondo AL
Arch Dermatol; 2007 Nov; 143(11):1369-71. PubMed ID: 18025359
[No Abstract] [Full Text] [Related]
14. Brimonidine for erythema caused by rosacea.
Drug Ther Bull; 2014 Dec; 52(12):138-40. PubMed ID: 25505014
[TBL] [Abstract][Full Text] [Related]
15. Devices and topical agents for rosacea management.
Mansouri Y; Goldenberg G
Cutis; 2014 Jul; 94(1):21-5. PubMed ID: 25101340
[TBL] [Abstract][Full Text] [Related]
16. Rosacea management: A comprehensive review.
Sharma A; Kroumpouzos G; Kassir M; Galadari H; Goren A; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 May; 21(5):1895-1904. PubMed ID: 35104917
[TBL] [Abstract][Full Text] [Related]
17. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
19. Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine.
Piwnica D; Rosignoli C; de Ménonville ST; Alvarez T; Schuppli Nollet M; Roye O; Jomard A; Aubert J
J Dermatol Sci; 2014 Jul; 75(1):49-54. PubMed ID: 24802713
[TBL] [Abstract][Full Text] [Related]
20. Rosacea: update on management and emerging therapies.
Fallen RS; Gooderham M
Skin Therapy Lett; 2012 Dec; 17(10):1-4. PubMed ID: 23223767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
